Abstract

10555 Background: Secondary mutations of KIT are commonly found in progressing lesions of imatinib (IM)-resistant GIST and represent a major factor of drug resistance. Development of salvage treatm...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call